This research proposes a pilot study using the combination of continuous glucose monitor (CGM) and insulin pump therapy, also known as sensor augmented pump (SAP) therapy, for cystic fibrosis related diabetes (CFRD) management in the inpatient setting, with the aim of improving glycemic control.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1
Incorporating both insulin pump and CGM technology together (also known as SAP therapy) has the potential to better optimize glycemic control than each device alone. Participants in this arm will receive their insulin dosing via insulin pump and their blood sugars will be monitored using a Continuous Glucose Monitor.
Participants assigned to this arm will receive conventional diabetes management with daily insulin injections (or on an insulin pump if already on an insulin pump in the outpatient setting) and capillary blood glucose monitoring. These participants will also wear a blinded Continuous Glucose Monitor (CGM) for outcome assessment.
Children's Hospital Colorado, University of Colorado Denver
Aurora, Colorado, United States
Differences in CGM percent time over 140 mg/dl
Differences in percent time \>140 mg/dl on CGM between groups
Time frame: through study completion, up to 3 weeks
Change in Pulmonary Function
Change in Pulmonary Function, FEV1 (percent and L), from admission to 1 week
Time frame: baseline and 1 week
Circulatory markers of inflammation
∆hsCRP and ∆calprotectin from admission to 1 week
Time frame: baseline and 1 week
Weight change
Change in weight from admission to 1 week
Time frame: baseline and 1 week
Statstrip glucose
glucose obtained from bedside glucometer (mg/dl)
Time frame: through study completion, up to 3 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.